Skip to main content
. 2017 Nov 24;24(1):1762–1769. doi: 10.1080/10717544.2017.1402216

Table 4.

Pharmacokinetic parameters of DH following the oral administration of Cymbalta® capsules and buccal administration of F2 (Mean ± SD).

Pharmacokinetic parameter Cymbalta® 30 mg capsule F2 films
Cmax (ng/ml) 54.10 ± 33.83 89.33 ± 34.21
Tmax (h) 5.67 ± 1.86 3.5 ± 0.84
AUC0–t (ng h/ml) 518.5 ± 333.32 1536.8 ± 931.45
AUC0–∞ (ng h/ml) 535.09 ± 337.01 1646.17 ± 1043.7
MRT (h) 20.99 ± 4.8 22.36 ± 4.32
K (1/h) 0.05 ± 0.01 0.05 ± 0.01
Relative bioavailability (%) 296.39